The United Kingdom and the United States have secured a important commercial pact that will ensure no import taxes on UK medicine products going into the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the NHS. This commitment guarantees that import taxes on these key goods will remain at zero for a duration of 36 months.
This deal is in response to recent warnings to significantly raise import taxes on patented drug imports, with figures mentioned up to 100%.
"This agreement between the United Kingdom reinforces the global environment for cutting-edge drugs and establishes long-overdue balance to American-British medicine commerce," a release declared.
Commercial Importance
Medicines are one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products worth billions to the US. This figure accounted for 17.4% of total UK exports in that span.
"This deal protects jobs, boosts investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The pact involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. Previously, rebates exceeded 20%.
Broader Context
The deal takes place against a long-running tension between the sector and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by assertions that American consumers were charged several times more for the same drugs than patients in the UK and Europe.
Recently, several major manufacturing plans in the UK have been delayed or abandoned, while substantial investments have been announced toward US facilities.
One official acknowledged that the NHS had to spend more on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
